Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

b interferon-free trial of PSI-7977 and/or PSI-938 in patients with all HCV genotypes. Mericitabine (RG7128) continues in development through a strategic collaboration with Roche.

   Contact
       Richard E. T. Smith, Ph.D.
       VP, Investor Relations and Corporate Communications
       Office +1 (609) 865-0693

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... BETHLEHEM, Pa. , Nov. 21, 2014 /PRNewswire/ ... drug eluting devices, has developed and manufactured a ... Institute (LPRI), the Research and Development arm of ... Vice President of Project Management at Particle Sciences, ... Particle Sciences utilizing our material sciences and modeling ...
(Date:11/22/2014)... , Nov. 21, 2014 Many ... Undoubtedly, the growing influence of patients in the ... marketing interactions. Now, more than ever, understanding how ... for medical products is essential. ... Practices, LLC, benchmarked companies spent about two-thirds of ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... October 25, 2011 International medical ... (NASDAQ OMX Stockholm: SECT B) , announces ... University Hospitals (UH) in Cleveland.   UH and ... medical imaging with the goals of improving patient care, ...
... SUNNYVALE, Calif., Oct. 25, 2011 ... premier radiation oncology company, today announced that the U.S. ... 510(k) clearance to market the Dose Control System (DCS), ... system performance.   The TomoTherapy System revolutionized ...
Cached Medicine Technology:Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 2Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 3Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 2Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 3
(Date:11/22/2014)... PrettyTailor , an outstanding dress ... big promotion. Customers can buy new dresses at its ... visit its website. , As a matter of fact, ... It mainly provides four types of wedding outfits, including ... girl dresses. It also provides a variety of occasion ...
(Date:11/22/2014)... is a famous brand in the bamboo flooring industry. ... bamboo mats ; the new models are offered now ... According to the sales manager of BambooFlooringChina.com, Bamboo is a ... resource. Their bamboo mats are 100% made from natural bamboo. ... bamboo with caramel bamboo strips. , “Bamboo mats ...
(Date:11/22/2014)... Discount-Dress.com is an important company ... is to increase the company’s online market share by a ... of bridesmaid dresses and announced a bridesmaid dress promotion for ... Dec. 30, 2014. All the dresses from this company are ... In fact, Discount-Dress.com is very good at manufacturing wedding dresses. ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in ... than 450 new signatures since the end of October, ... people had signed the petition as of November 21st, ... October 31st, when 86,042 supporters had signed on to ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
Breaking Medicine News(10 mins):Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... $12 million grant from the National Institutes of Health ... medication of choice for preventing migraines in children and ... and adolescents in the United States, with an annual ... FDA-approved medication to prevent childhood migraines and there are ...
... experience more chronic musculoskeletal pain, suggests a new study led ... women over the age of 18 were surveyed on their ... the analysis were fibromyalgia, sciatica, chronic neck pain, chronic back ... all over the body. Results showed that women who ...
... Pediatricians in Appalachia are less likely than doctors in ... the human papillomavirus (HPV) vaccine, according to a new study. ... most important risk factor for cervical cancer and studies ... cancer and to die from it than women living elsewhere. ...
... long been an attractive class of drug candidates because ... potential side effects. Dr. Andrei Yudin, Professor, Department ... and effective process that makes linear peptides circular, which ... effectively and increase their stability compared to linear peptides. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... colon cancer screening earlier than women, new research suggests. ... have potentially precancerous lesions (also called polyps or adenomas) in ... percent of women -- and to have them at an ...
... documenting patients, preferences for care at the end of life ... A new study published today in the Journal of ... physicians about end-of-life care and have an advance directive in ... do not have these discussions and documents. The study ...
Cached Medicine News:Health News:Cincinnati Children's earns $12 million NIH grant to test migraine prevention medicines 2Health News:Study shows link between smoking and chronic pain in women 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 3Health News:OGI and MaRS Innovation invest in peptide therapeutics 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3
The Dolphin Medical 2150 Pulse Oximeter consists of the Dolphin ONE OEM 701 Module technology, (1) extension cable, and (1) oximetry sensor to non-invasively calculate the functional saturation of ar...
All-in-One Fingertip Oximeter...
... The Invacare Sleep Printing ... specifically designed to address ... a device that can ... conducting overnight screening for ...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: